Affordable Access

Access to the full text

Comparison of the Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema in Vitrectomized and Nonvitrectomized Eyes

Authors
  • Koyanagi, Yoshito
  • Yoshida, Shigeo
  • Kobayashi, Yoshiyuki
  • Kubo, Yuki
  • Yamaguchi, Muneo
  • Nakama, Takahito
  • Nakao, Shintaro
  • Ikeda, Yasuhiro
  • Ohshima, Yuji
  • Ishibashi, Tatsuro
  • Sonoda, Koh-hei
Type
Published Article
Journal
Ophthalmologica
Publisher
S. Karger AG
Publication Date
Jul 01, 2016
Volume
236
Issue
2
Pages
67–73
Identifiers
DOI: 10.1159/000446992
PMID: 27362944
Source
Karger
Keywords
License
Green
External links

Abstract

Purpose: To compare the effectiveness of intravitreal ranibizumab (IVR) for diabetic macular edema (DME) between eyes with and without previous vitrectomy. Procedures: We prospectively assessed the best-corrected visual acuity (BCVA) and central macular thickness (CMT) after IVR for 6 months. Results: There were no significant differences in the baseline BCVA and CMT between both groups. In the nonvitrectomized group (n = 15), the mean changes of BCVA and CMT from baseline to month 6 were significant (p < 0.01). In the vitrectomized group (n = 10), the improvement appeared to be slower, and the mean BCVA improvement was not significant (p = 0.5), although the mean CMT decrease was significant (p < 0.05). There were no significant differences in the mean changes of BCVA and CMT between both groups at 6 months. Conclusions: The difference in the effectiveness of IVR between both groups was not significant. IVR can be a treatment option even for vitrectomized DME eyes.

Report this publication

Statistics

Seen <100 times